tiprankstipranks
CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
US Market
GDTC
CytoMed Therapeutics Limited
RESEARCH TOOLSreports
Want to see GDTC full AI Analyst Report?

CytoMed Therapeutics Limited (GDTC) Ratios

23 Followers

CytoMed Therapeutics Limited Ratios

GDTC's free cash flow for Q4 2025 was $-3.31. For the 2025 fiscal year, GDTC's free cash flow was decreased by $ and operating cash flow was $-14.03. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Mar 24Dec 22
Liquidity Ratios
Current Ratio
 5.17 5.17 9.89 14.08 0.60
Quick Ratio
 5.17 5.17 8.51 13.14 0.46
Cash Ratio
 2.95 2.95 8.19 12.55 0.38
Solvency Ratio
 -3.71 -3.27 -2.39 -3.58 -0.57
Operating Cash Flow Ratio
 -6.17 -5.21 -4.47 -4.93 -0.34
Short-Term Operating Cash Flow Coverage
 -107.14 -90.52 -71.98 -104.09 -0.37
Net Current Asset Value
$ 2.53M$ 2.53M$ 3.64M$ 6.80M$ -1.60M
Leverage Ratios
Debt-to-Assets Ratio
 0.06 0.06 0.05 0.04 0.81
Debt-to-Equity Ratio
 0.07 0.07 0.05 0.04 7.19
Debt-to-Capital Ratio
 0.07 0.07 0.05 0.04 0.88
Long-Term Debt-to-Capital Ratio
 0.05 0.05 0.04 0.03 0.44
Financial Leverage Ratio
 1.22 1.22 1.12 1.10 8.90
Debt Service Coverage Ratio
 -60.22 -69.96 -41.87 -45.99 -0.38
Interest Coverage Ratio
 -152.16 -219.72 -172.79 -83.79 -18.69
Debt to Market Cap
 0.03 0.03 <0.01 <0.01 0.10
Interest Debt Per Share
 0.04 0.04 0.03 0.04 0.41
Net Debt to EBITDA
 0.38 0.38 1.84 2.20 -1.80
Profitability Margins
Gross Profit Margin
-63.95%-277.74%100.72%131.44%0.00%
EBIT Margin
-1079.86%-1415.96%-3619.16%-1037.76%0.00%
EBITDA Margin
-1002.72%-1346.05%-3443.05%-1011.10%0.00%
Operating Profit Margin
-1075.12%-1415.96%-5049.84%-1100.96%0.00%
Pretax Profit Margin
-1066.16%-1231.97%-3628.58%-1058.90%0.00%
Net Profit Margin
-1062.06%-1227.07%-3621.15%-1077.85%0.00%
Continuous Operations Profit Margin
-1066.16%-1231.97%-3628.58%-1077.92%0.00%
Net Income Per EBT
99.61%99.60%99.80%101.79%100.04%
EBT Per EBIT
99.17%87.01%71.86%96.18%133.76%
Return on Assets (ROA)
-56.68%-49.05%-25.55%-33.41%-58.18%
Return on Equity (ROE)
-75.27%-59.85%-28.68%-36.75%-518.13%
Return on Capital Employed (ROCE)
-62.96%-62.12%-37.91%-36.23%-214.03%
Return on Invested Capital (ROIC)
-62.45%-61.61%-37.73%-36.11%-47.29%
Return on Tangible Assets
-57.58%-49.83%-25.78%-33.45%-58.39%
Earnings Yield
-33.97%-25.10%-4.80%-6.01%-7.17%
Efficiency Ratios
Receivables Turnover
 3.23 2.42 3.78 0.00 0.00
Payables Turnover
 6.00 9.67 0.80 0.15 7.42
Inventory Turnover
 0.00 0.00 0.04 <0.01 0.19
Fixed Asset Turnover
 0.12 0.09 0.02 0.19 0.00
Asset Turnover
 0.05 0.04 <0.01 0.03 0.00
Working Capital Turnover Ratio
 0.15 0.09 <0.01 0.10 0.00
Cash Conversion Cycle
 52.28 113.24 9.50K 64.06K 1.89K
Days of Sales Outstanding
 113.12 151.00 96.52 0.00 0.00
Days of Inventory Outstanding
 0.00 0.00 9.86K 66.48K 1.94K
Days of Payables Outstanding
 60.84 37.76 454.17 2.41K 49.19
Operating Cycle
 113.12 151.00 9.96K 66.48K 1.94K
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.37 -0.32 -0.17 -0.25 -0.13
Free Cash Flow Per Share
 -0.44 -0.38 -0.26 -0.26 -0.18
CapEx Per Share
 0.07 0.06 0.09 <0.01 0.04
Free Cash Flow to Operating Cash Flow
 1.20 1.19 1.52 1.02 1.34
Dividend Paid and CapEx Coverage Ratio
 -5.03 -5.26 -1.94 -60.57 -2.95
Capital Expenditure Coverage Ratio
 -5.03 -5.26 -1.94 -60.57 -2.95
Operating Cash Flow Coverage Ratio
 -9.07 -7.66 -5.85 -7.88 -0.33
Operating Cash Flow to Sales Ratio
 -10.27 -11.58 -38.16 -9.21 0.00
Free Cash Flow Yield
-39.23%-28.20%-7.67%-5.22%-4.41%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -2.94 -3.98 -20.83 -16.63 -13.94
Price-to-Sales (P/S) Ratio
 31.38 48.89 754.46 179.27 0.00
Price-to-Book (P/B) Ratio
 2.04 2.38 5.98 6.11 72.24
Price-to-Free Cash Flow (P/FCF) Ratio
 -2.55 -3.55 -13.04 -19.15 -22.65
Price-to-Operating Cash Flow Ratio
 -3.04 -4.22 -19.77 -19.47 -30.32
Price-to-Earnings Growth (PEG) Ratio
 0.11 -0.04 0.46 4.99 -0.38
Price-to-Fair Value
 2.04 2.38 5.98 6.11 72.24
Enterprise Value Multiple
 -2.75 -3.26 -20.07 -15.53 -30.71
Enterprise Value
 11.76M 13.99M 35.94M 45.61M 33.63M
EV to EBITDA
 -2.75 -3.26 -20.07 -15.53 -30.71
EV to Sales
 27.59 43.84 691.00 156.98 0.00
EV to Free Cash Flow
 -2.24 -3.18 -11.94 -16.77 -24.06
EV to Operating Cash Flow
 -2.69 -3.78 -18.11 -17.05 -32.21
Tangible Book Value Per Share
 0.57 0.58 0.57 0.80 0.05
Shareholders’ Equity Per Share
 0.56 0.56 0.57 0.80 0.06
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.00 >-0.01 >-0.01
Revenue Per Share
 0.04 0.03 <0.01 0.03 0.00
Net Income Per Share
 -0.38 -0.34 -0.16 -0.29 -0.29
Tax Burden
 1.00 1.00 1.00 1.02 1.00
Interest Burden
 0.99 0.87 1.00 1.02 1.63
Research & Development to Revenue
 5.36 6.84 27.48 4.15 0.00
SG&A to Revenue
 2.73 4.52 24.34 1.18 0.00
Stock-Based Compensation to Revenue
 0.00 2.17 0.00 0.00 0.00
Income Quality
 0.91 0.93 1.08 0.85 0.45
Currency in USD